To further investigate the specific clinical impact of p-FAK in patients treated with EGFR-TKIs, we conducted IHC analysis in a cohort of NSCLC patients who received EGFR-TKI therapy. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.